精神疾病诊断与COVID-19患者死亡风险的关联
这项回顾性队列研究纳入纽约大型学术医疗系统7348例实验室确诊COVID-19成人患者,随访45天。调整人口学和医学危险因素后,精神分裂症谱系障碍诊断与死亡显著相关(OR 2.67;95%CI 1.48-4.80),而心境障碍和焦虑障碍与死亡无显著关联。
要点
- 精神分裂症谱系障碍与COVID-19患者45天内死亡风险显著增加相关。
- 心境障碍和焦虑障碍诊断与死亡风险无显著关联。
- 精神分裂症与死亡关联强度仅次于年龄。
核心结论
- 在SARS-CoV-2阳性成人中,精神分裂症谱系障碍诊断与死亡风险增加相关,心境障碍和焦虑障碍诊断与死亡风险无显著关联。
研究设计与样本
- 回顾性队列研究,纳入纽约大型学术医疗系统2020年3月3日至5月31日实验室确诊COVID-19的7348例连续成人患者,随访45天。
主要发现
- 7348例阳性患者中,75例(1.0%)有精神分裂症谱系疾病史,564例(7.7%)有心境障碍史,360例(4.9%)有焦虑障碍史。
- 调整人口学和医学危险因素后,精神分裂症谱系障碍与死亡显著相关(OR 2.67;95%CI 1.48-4.80)。
- 心境障碍(OR 1.14;95%CI 0.87-1.49)和焦虑障碍(OR 0.96;95%CI 0.65-1.41)调整后与死亡无显著关联。
- 与其他危险因素相比,精神分裂症诊断与死亡关联强度仅次于年龄。
关键数值与推荐
- 暴露分类基于检测前国际疾病分类第十版临床修改版诊断:精神分裂症谱系障碍、心境障碍、焦虑障碍。
- 主要结局为SARS-CoV-2阳性检测后45天内死亡或出院转临终关怀。
临床怎么用
- 对COVID-19患者评估死亡风险时,应关注精神分裂症谱系障碍病史这一潜在危险因素。
局限性
- 本研究为回顾性队列设计,仅反映纽约大型学术医疗系统单中心数据,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: To date, the association of psychiatric diagnoses with mortality in patients infected with coronavirus disease 2019 (COVID-19) has not been evaluated. OBJECTIVE: To assess whether a diagnosis of a schizophrenia spectrum disorder, mood disorder, or anxiety disorder is associated with mortality in patients with COVID-19. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study assessed 7348 consecutive adult patients for 45 days following laboratory-confirmed COVID-19 between March 3 and May 31, 2020, in a large academic medical system in New York. The final date of follow-up was July 15, 2020. Patients without available medical records before testing were excluded. EXPOSURES: Patients were categorized based on the following International Statistical Classification of Diseases, Tenth Revision, Clinical Modification diagnoses before their testing date: (1) schizophrenia spectrum disorders, (2) mood disorders, and (3) anxiety disorders. Patients with these diagnoses were compared with a reference group without psychiatric disorders. MAIN OUTCOMES AND MEASURES: Mortality, defined as death or discharge to hospice within 45 days following a positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) test result. RESULTS: Of the 26 540 patients tested, 7348 tested positive for SARS-CoV-2 (mean [SD] age, 54 [18.6] years; 3891 [53.0%] women). Of eligible patients with positive test results, 75 patients (1.0%) had a history of a schizophrenia spectrum illness, 564 (7.7%) had a history of a mood disorder, and 360 (4.9%) had a history of an anxiety disorder. After adjusting for demographic and medical risk factors, a premorbid diagnosis of a schizophrenia spectrum disorder was significantly associated with mortality (odds ratio [OR], 2.67; 95% CI, 1.48-4.80). Diagnoses of mood disorders (OR, 1.14; 95% CI, 0.87-1.49) and anxiety disorders (OR, 0.96; 95% CI, 0.65-1.41) were not associated with mortality after adjustment. In comparison with other risk factors, a diagnosis of schizophrenia ranked behind only age in strength of an association with mortality. CONCLUSIONS AND RELEVANCE: In this cohort study of adults with SARS-CoV-2-positive test results in a large New York medical system, adults with a schizophrenia spectrum disorder diagnosis were associated with an increased risk for mortality, but those with mood and anxiety disorders were not associated with a risk of mortality. These results suggest that schizophrenia spectrum disorders may be a risk factor for mortality in patients with COVID-19.
引用
- Nemani K, Li C, Olfson M, et al. Association of Psychiatric Disorders With Mortality Among Patients With COVID-19. JAMA Psychiatry. 2021. PMID: 33502436. doi:10.1001/jamapsychiatry.2020.4442
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。